reverses diabetes type 2

🔥+ reverses diabetes type 2 25 May 2020 Or maybe you've been living with it for awhile. Here's the thing: your journey is unique and it starts fresh every day. No matter where you are with type 2 diabetes, ...

reverses diabetes type 2 Endocrine Today

diabetes diabetes icd 10
Skip to main content

Main menu

the 1 last update 25 May 2020 SearchSearch

Position Statements
  1. American Diabetes Association
Diabetes for 1 last update 25 May 2020 Care Diabetes Care reverses diabetes type 2 with fasting (☑ is characterized by) | reverses diabetes type 2 jewelryhow to reverses diabetes type 2 for 2019 Jan; for 1 last update 25 May 2020 4242(Supplement 1): S61reverses diabetes type 2 characteristics (👍 treatment and prevention) | reverses diabetes type 2 and alcoholhow to reverses diabetes type 2 for -S70. reverses diabetes type 2 oral medications (☑ young adults early death) | reverses diabetes type 2 yogahow to reverses diabetes type 2 for https://doi.org/10.2337/dc19-S006

Abstract

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

ASSESSMENT OF GLYCEMIC CONTROL

Glycemic management is primarily assessed with the A1C test, which was the measure studied in clinical trials demonstrating the benefits of improved glycemic control. Patient self-monitoring of blood glucose (SMBG) may help with self-management and medication adjustment, particularly in individuals taking insulin. Continuous glucose monitoring (CGM) also has an important role in assessing the effectiveness and safety of treatment in many patients with type 1 diabetes, and limited data suggest it may also be helpful in selected patients with type 2 diabetes, such as those on intensive insulin regimens (1).

reverses diabetes type 2 good foods to eat (🔴 statistics australia) | reverses diabetes type 2 toolshow to reverses diabetes type 2 for A1C Testing

Recommendations

  • 6.1 Perform the A1C test at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control). E

  • 6.2 Perform the A1C test quarterly in patients whose therapy has changed or who are not meeting glycemic goals. E

  • 6.3 Point-of-care testing for A1C provides the opportunity for more timely treatment changes. E

A1C reflects average glycemia over approximately 3 months. The performance of the test is generally excellent for NGSP-certified assays (www.ngsp.org). The test is the major tool for assessing glycemic control and has strong predictive value for diabetes complications (13). Thus, A1C testing should be performed routinely in all patients with diabetes—at initial assessment and as part of continuing care. Measurement approximately every 3 months determines whether patients’ glycemic targets have been reached and maintained. The frequency of A1C testing should depend on the clinical situation, the treatment regimen, and the clinician’s judgment. The use of point-of-care A1C testing may provide an opportunity for more timely treatment changes during encounters between patients and providers. Patients with type 2 diabetes with stable glycemia well within target may do well with A1C testing only twice per year. Unstable or intensively managed patients (e.g., pregnant women with type 1 diabetes) may require testing more frequently than every 3 months (4).

A1C Limitations

The A1C test is an indirect measure of average glycemia and, as such, is subject to limitations. As with any laboratory test, there is variability in the measurement of A1C. Although such variability is less on an intraindividual basis than that of blood glucose measurements, clinicians should exercise judgment when using A1C as the sole basis for assessing glycemic control, particularly if the result is close to the threshold that might prompt a change in medication therapy. Conditions that affect red blood cell turnover (hemolytic and other anemias, glucose-6-phosphate dehydrogenase deficiency, recent blood transfusion, use of drugs that stimulate erythropoesis, end-stage kidney disease, and pregnancy) may result in discrepancies between the A1C result and the patient’s true mean glycemia. Hemoglobin variants must be considered, particularly when the A1C result does not correlate with the patient’s SMBG levels. However, most assays in use in the U.S. are accurate in individuals heterozygous for the most common variants (www.ngsp.org/interf.asp). Other measures of average glycemia such as fructosamine and 1,5-anhydroglucitol are available, but their translation into average glucose levels and their prognostic significance are not as clear as for A1C. Though some variability in the relationship between average glucose levels and A1C exists among different individuals, generally the association between mean glucose and A1C within an individual correlates over time (5).

A1C does not provide a measure of glycemic variability or hypoglycemia. For patients prone to glycemic variability, especially patients with type 1 diabetes or type 2 diabetes with severe insulin deficiency, glycemic control is best evaluated by the combination of results from SMBG or CGM and A1C. A1C may also inform the accuracy of the patient’s meter (or the patient’s reported SMBG results) and the adequacy of the SMBG testing schedule.

A1C and Mean Glucose

Table 6.1 shows the correlation between A1C levels and mean glucose levels based on two studies: the international A1C-Derived Average Glucose (ADAG) study, which assessed the correlation between A1C and frequent SMBG and CGM in 507 adults (83% non-Hispanic whites) with type 1, type 2, and no diabetes (6), and an empirical study of the average blood glucose levels at premeal, postmeal, and bedtime associated with specified A1C levels using data from the ADAG trial (7). The American Diabetes Association (ADA) and the American Association for Clinical Chemistry have determined that the correlation (r = 0.92) in the ADAG trial is strong enough to justify reporting both the A1C result and the estimated average glucose (eAG) result when a clinician orders the A1C test. Clinicians should note that the mean plasma glucose numbers in the table are based on ∼2,700 readings per A1C in the ADAG trial. In a recent report, mean glucose measured with CGM versus central laboratory–measured A1C in 387 participants in three randomized trials demonstrated that A1C may underestimate or overestimate mean glucose (5). Thus, as suggested, a patient’s CGM profile has considerable potential for optimizing his or her glycemic management (5).

View this table:
Table 6.1

Mean glucose levels for specified A1C levels (6,7)

A1C Differences in Ethnic Populations and Children

In the ADAG study, there were no significant differences among racial and ethnic groups in the regression lines between A1C and mean glucose, although the study was underpowered to detect a difference and there was a trend toward a difference between the African/African American and non-Hispanic white cohorts, with higher A1C values observed in Africans/African Americans compared with non-Hispanic whites for a given mean glucose. Other studies have also demonstrated higher A1C levels in African Americans than in whites at a given mean glucose concentration (8,9).

A1C assays are available that do not demonstrate a statistically significant difference in individuals with hemoglobin variants. Other assays have statistically significant interference, but the difference is not clinically significant. Use of an assay with such statistically significant interference may explain a report that for any level of mean glycemia, African Americans heterozygous for the common hemoglobin variant HbS had lower A1C by about 0.3 percentage points when compared with those without the trait (10,11). Another genetic variant, X-linked glucose-6-phosphate dehydrogenase G202A, carried by 11% of African Americans, was associated with a decrease in A1C of about 0.8% in hemizygous men and 0.7% in homozygous women compared with those without the trait (12).

A small study comparing A1C to CGM data in children with type 1 diabetes found a highly statistically significant correlation between A1C and mean blood glucose, although the correlation (r = 0.7) was significantly lower than in the ADAG trial (13). Whether there are clinically meaningful differences in how A1C relates to average glucose in children or in different ethnicities is an area for further study (8,14,15). Until further evidence is available, it seems prudent to establish A1C goals in these populations with consideration of both individualized SMBG and A1C results.

Glucose Assessment

For many people with diabetes, glucose monitoring is key for the achievement of glycemic targets. Major clinical trials of insulin-treated patients have included SMBG as part of multifactorial interventions to demonstrate the benefit of intensive glycemic control on diabetes complications (16). SMBG is thus an integral component of effective therapy of patients taking insulin. In recent years, CGM has emerged as a complementary method for the the 1 last update 25 May 2020 assessment of glucose levels. Glucose monitoring allows patients to evaluate their individual response to therapy and assess whether glycemic targets are being safely achieved. Integrating results into diabetes management can be a useful tool for guiding medical nutrition therapy and physical activity, preventing hypoglycemia, and adjusting medications (particularly prandial insulin doses). The patient’s specific needs and goals should dictate SMBG frequency and timing or the consideration of CGM use. Please refer to Section 7 “Diabetes Technology” for a fuller discussion of the use of SMBG and CGM.For many people with diabetes, glucose monitoring is key for the achievement of glycemic targets. Major clinical trials of insulin-treated patients have included SMBG as part of multifactorial interventions to demonstrate the benefit of intensive glycemic control on diabetes complications (16). SMBG is thus an integral component of effective therapy of patients taking insulin. In recent years, CGM has emerged as a complementary method for the assessment of glucose levels. Glucose monitoring allows patients to evaluate their individual response to therapy and assess whether glycemic targets are being safely achieved. Integrating results into diabetes management can be a useful tool for guiding medical nutrition therapy and physical activity, preventing hypoglycemia, and adjusting medications (particularly prandial insulin doses). The patient’s specific needs and goals should dictate SMBG frequency and timing or the consideration of CGM use. Please refer to Section 7 “Diabetes Technology” for a fuller discussion of the use of SMBG and CGM.

A1C GOALS

For glycemic goals in older adults, please refer to Section 12 “Older Adults.” For glycemic goals in children, please refer to Section 13 “Children and Adolescents.” For glycemic goals in pregnant women, please refer to Section 14 “Management of Diabetes in Pregnancy.”

Recommendations

  • 6.4 A reasonable A1C goal for many nonpregnant adults is <7% (53 mmol/mol). A

  • 6.5 Providers might reasonably suggest more stringent A1C goals (such as <6.5% [48 mmol/mol]) for selected individual patients if this can be achieved without significant hypoglycemia or other adverse effects of treatment (i.e., polypharmacy). Appropriate patients might include those with short duration of diabetes, type 2 diabetes treated with lifestyle or metformin only, long life expectancy, or no significant cardiovascular disease. C

  • reverses diabetes type 2 with hyperglycemia icd 10 (🔴 case study) | reverses diabetes type 2 exhaustionhow to reverses diabetes type 2 for 6.6 Less stringent A1C goals (such as <8% [64 mmol/mol]) may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions, or long-standing diabetes in whom the goal is difficult to achieve despite diabetes self-management education, appropriate glucose monitoring, and effective doses of multiple glucose-lowering agents including insulin. B

  • 6.7 Reassess glycemic targets over time based on the criteria in Fig. 6.1 or, in older adults, Table 12.1. E

Figure the 1 last update 25 May 2020 6.1Figure 6.1

Depicted are patient and disease factors used to determine optimal A1C targets. Characteristics and predicaments toward the left justify more stringent efforts to lower A1C; those toward the right suggest less stringent efforts. A1C 7% = 53 mmol/mol. Adapted with permission from Inzucchi et al. (40).

A1C and Microvascular Complications

Hyperglycemia defines diabetes, and glycemic control is fundamental to diabetes management. The Diabetes Control and Complications Trial (DCCT) (16), a prospective randomized controlled trial of intensive (mean A1C about 7% [53 mmol/mol]) versus standard (mean A1C about 9% [75 mmol/mol]) glycemic control in patients with type 1 diabetes, showed definitively that better glycemic control is associated with 50–76% reductions in rates of development and progression of microvascular (retinopathy, neuropathy, and diabetic kidney disease) complications. Follow-up of the DCCT cohorts in the Epidemiology of Diabetes Interventions and Complications (EDIC) study (17,18) demonstrated persistence of these microvascular benefits over two decades despite the fact that the glycemic separation between the treatment groups diminished and disappeared during follow-up.

The Kumamoto Study (19) and UK Prospective Diabetes Study (UKPDS) (20,21) confirmed that intensive glycemic control significantly decreased rates of microvascular complications in patients with short-duration type 2 diabetes. Long-term follow-up of the UKPDS cohorts showed enduring effects of early glycemic control on most microvascular complications (22).

Therefore, achieving A1C targets of <7% (53 mmol/mol) has been shown to reduce microvascular complications of type 1 and type 2 diabetes when instituted early in the course of disease. Epidemiologic analyses of the DCCT (16) and UKPDS (23) demonstrate a curvilinear relationship between A1C and microvascular complications. Such analyses suggest that, on a population level, the greatest number of complications will be averted by taking patients from very poor control to fair/good control. These analyses also suggest that further lowering of A1C from 7% to 6% [53 mmol/mol to 42 mmol/mol] is associated with further reduction in the risk of microvascular complications, although the absolute risk reductions become much smaller. Given the substantially increased risk of hypoglycemia in type 1 diabetes trials and with polypharmacy in type 2 diabetes, the risks of lower glycemic targets may outweigh the potential benefits on microvascular complications.

Three landmark trials (Action to Control Cardiovascular Risk in Diabetes [ACCORD], Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation [ADVANCE], and Veterans Affairs Diabetes Trial [VADT]) were conducted to test the effects of near normalization of blood glucose on cardiovascular outcomes in individuals with long-standing type 2 diabetes and either known cardiovascular disease (CVD) or high cardiovascular risk. These trials showed that lower A1C levels were associated with reduced onset or progression of some microvascular complications (2426).

The concerning mortality findings in the ACCORD trial (27), discussed below, and the relatively intense efforts required to achieve near euglycemia should also be considered when setting glycemic targets for individuals with longstanding diabetes such as those studied in ACCORD, ADVANCE, and VADT. Findings from these studies suggest caution is needed in treating diabetes aggressively to near-normal A1C goals in people with long-standing type 2 diabetes with or at significant risk of CVD. However, on the basis of physician judgment and patient preferences, select patients, especially those with little comorbidity and long life expectancy, may benefit from adopting more intensive glycemic targets (e.g., A1C target <6.5% [48 mmol/mol]) if they can achieve it safely without hypoglycemia or significant therapeutic burden.

A1C and Cardiovascular Disease Outcomes

Cardiovascular Disease and Type 1 Diabetes

CVD is a more common cause of death than microvascular complications in populations with diabetes. There is evidence for a cardiovascular benefit of intensive glycemic control after long-term follow-up of cohorts treated early in the course of type 1 diabetes. In the DCCT, there was a trend toward lower risk of CVD events with intensive control. In the 9-year post-DCCT follow-up of the EDIC cohort, participants previously randomized to the intensive arm had a significant 57% reduction in the risk of nonfatal myocardial infarction (MI), stroke, or cardiovascular death compared with those previously randomized to the standard arm (28). The benefit of intensive glycemic control in this cohort with type 1 diabetes has been shown to persist for several decades (29) and to be associated with a modest reduction in all-cause mortality (30).

Cardiovascular Disease and Type 2 Diabetes

In type 2 diabetes, there is evidence that more intensive treatment of glycemia in newly diagnosed patients may reduce long-term CVD rates. During the UKPDS, there was a 16% reduction in CVD events (combined fatal or nonfatal MI and sudden death) in the intensive glycemic control arm that did not reach statistical significance (P = 0.052), and there was no suggestion of benefit on other CVD outcomes (e.g., stroke). However, after 10 years of observational follow-up, those originally randomized to intensive glycemic control had significant long-term reductions in MI (15% with sulfonylurea or insulin as initial pharmacotherapy, 33% with metformin as initial pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (22).

ACCORD, ADVANCE, and VADT suggested no significant reduction in CVD outcomes with intensive glycemic control in participants followed for shorter durations (3.5–5.6 years) and who had more advanced type 2 diabetes than UKPDS participants. All three trials were conducted in relatively older participants with longer known duration of diabetes (mean duration 8–11 years) and either CVD or multiple cardiovascular risk factors. The target A1C among intensive-control subjects was <6% (42 mmol/mol) in ACCORD, <6.5% (48 mmol/mol) in ADVANCE, and a 1.5% reduction in A1C compared with control subjects in VADT, with achieved A1C of 6.4% vs. 7.5% (46 mmol/mol vs. 58 mmol/mol) in ACCORD, 6.5% vs. 7.3% (48 mmol/mol vs. 56 mmol/mol) in ADVANCE, and 6.9% vs. 8.4% (52 mmol/mol vs. 68 mmol/mol) in VADT. Details of these studies are reviewed extensively in “Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials” (31).

The glycemic control comparison in ACCORD was halted early due to an increased mortality rate in the intensive compared with the standard treatment arm (1.41% vs. 1.14% per year; hazard ratio 1.22 [95% CI 1.01–1.46]), with a similar increase in cardiovascular deaths. Analysis of the ACCORD data did not identify a clear explanation for the excess mortality in the intensive treatment arm (27).

Longer-term follow-up has shown no evidence of cardiovascular benefit or harm in the ADVANCE trial (32). The end-stage renal disease rate was lower in the intensive treatment group over follow-up. However, 10-year follow-up of the VADT cohort (33) showed a reduction in the risk of cardiovascular events (52.7 [control group] vs. 44.1 [intervention group] events per 1,000 person-years) with no benefit in cardiovascular or overall mortality. Heterogeneity of mortality effects across studies was noted, which may reflect differences in glycemic targets, therapeutic approaches, and population characteristics (34).

Mortality findings in ACCORD (27) and subgroup analyses of VADT (35) suggest that the potential risks of intensive glycemic control may outweigh its benefits in higher-risk patients. In all three trials, severe hypoglycemia was significantly more likely in participants who were randomly assigned to the intensive glycemic control arm. Those patients with long duration of diabetes, a known history of hypoglycemia, advanced atherosclerosis, or advanced age/frailty may benefit from less aggressive targets (36,37).

As discussed further below, severe hypoglycemia is a potent marker of high absolute risk of cardiovascular events and mortality (38). Providers should be vigilant in preventing hypoglycemia and should not aggressively attempt to achieve near-normal A1C levels in patients in whom such targets cannot be safely and reasonably achieved.

As discussed in Section 9 “Pharmacologic Approaches to Glycemic Treatment,” addition of specific sodium–glucose cotransporter 2 inhibitors (SGLT2i) or glucagon-like peptide 1 receptor agonists (GLP-1 RA) to improve cardiovascular outcomes in patients with established CVD is indicated with consideration for 1 last update 25 May 2020 of glycemic goals. If the patient is not at A1C target, continue metformin unless contraindicated and add SGLT2i or GLP-1 RA with proven cardiovascular benefit. If the patient is meeting A1C target, consider one of three strategies (39): As discussed in Section 9 “Pharmacologic Approaches to Glycemic Treatment,” addition of specific sodium–glucose cotransporter 2 inhibitors (SGLT2i) or glucagon-like peptide 1 receptor agonists (GLP-1 RA) to improve cardiovascular outcomes in patients with established CVD is indicated with consideration of glycemic goals. If the patient is not at A1C target, continue metformin unless contraindicated and add SGLT2i or GLP-1 RA with proven cardiovascular benefit. If the patient is meeting A1C target, consider one of three strategies (39):

  • 1. If already on dual therapy or multiple glucose-lowering therapies and not on an SGLT2i the 1 last update 25 May 2020 or GLP-1 RA, consider switching to one of these agents with proven cardiovascular benefit.1. If already on dual therapy or multiple glucose-lowering therapies and not on an SGLT2i or GLP-1 RA, consider switching to one of these agents with proven cardiovascular benefit.

  • 2. Reconsider/lower individualized A1C target and introduce SGLT2i or for 1 last update 25 May 2020 GLP-1 RA.2. Reconsider/lower individualized A1C target and introduce SGLT2i or GLP-1 RA.

  • 3. Reassess A1C at 3-month intervals and add SGLT2i or GLP-1 RA if A1C goes above target.

Setting and Modifying A1C Goals

Numerous factors must be considered when setting glycemic targets. The ADA proposes general targets appropriate for many patients but emphasizes the importance of individualization based on key patient characteristics. Glycemic targets must be individualized in the context of shared decision making to address the needs and preferences of each patient and the individual characteristics that influence risks and benefits of therapy for each patient.

The factors to consider in individualizing goals are depicted in Fig. 6.1. Figure 6.1 is not designed to be applied rigidly but to be used as a broad construct to guide clinical decision making (40) in both type 1 and type 2 diabetes. More stringent control (such as an A1C of 6.5% [48 mmol/mol] or <7% [53 mmol/mol]) may be recommended if it can be achieved safely and with acceptable burden of therapy and if life expectancy is sufficient to reap benefits of tight control. Less stringent control (A1C up to 8% [64 mmol/mol]) may be recommended if the life expectancy of the patient is such that the benefits of an intensive goal may not be realized, or if the risks and burdens outweigh the potential benefits. Severe or frequent hypoglycemia is an absolute indication for the modification of treatment regimens, including setting higher glycemic goals.

Diabetes is a chronic disease that progresses over decades. Thus, a goal that might be appropriate for an individual early in the course of the disease may change over time. Newly diagnosed patients and/or those without comorbidities that limit life expectancy may benefit from intensive control proven to prevent microvascular complications. Both DCCT/EDIC and UKPDS demonstrated metabolic memory, or a legacy effect, in which a finite period of intensive control yielded benefits that extended for decades after that control ended. Thus, a finite period of intensive control to near-normal A1C may yield enduring benefits even if control is subsequently deintensified as patient characteristics change. Over time, comorbidities may emerge, decreasing life expectancy and the potential to reap benefits from intensive control. Also, with longer duration of disease, diabetes may become more difficult to control, with increasing risks and burdens of therapy. Thus, A1C targets should be reevaluated over time to balance the risks and benefits as patient factors change.

reverses diabetes type 2 means (👍 values) | reverses diabetes type 2 blood pressurehow to reverses diabetes type 2 for Recommended glycemic targets for many nonpregnant adults are shown in Table 6.2. The recommendations include blood glucose levels that appear to correlate with achievement of an A1C of <7% (53 mmol/mol). The issue of preprandial versus postprandial SMBG targets is complex (41). Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, but intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C. In subjects with diabetes, surrogate measures of vascular pathology, such as endothelial dysfunction, are negatively affected by postprandial hyperglycemia. It is clear that postprandial hyperglycemia, like preprandial hyperglycemia, contributes to elevated A1C levels, with its relative contribution being greater at A1C levels that are closer to 7% (53 mmol/mol). However, outcome studies have clearly shown A1C to be the primary predictor of complications, and landmark trials of glycemic control such as the DCCT and UKPDS relied overwhelmingly on preprandial SMBG. Additionally, a randomized controlled for 1 last update 25 May 2020 trial in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (42). Therefore, it is reasonable for postprandial testing to be recommended for individuals who have premeal glucose values within target but have A1C values above target. Measuring postprandial plasma glucose 1–2 h after the start of a meal and using treatments aimed at reducing postprandial plasma glucose values to <180 mg/dL (10.0 mmol/L) may help to lower A1C.Recommended glycemic targets for many nonpregnant adults are shown in Table 6.2. The recommendations include blood glucose levels that appear to correlate with achievement of an A1C of <7% (53 mmol/mol). The issue of preprandial versus postprandial SMBG targets is complex (41). Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, but intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C. In subjects with diabetes, surrogate measures of vascular pathology, such as endothelial dysfunction, are negatively affected by postprandial hyperglycemia. It is clear that postprandial hyperglycemia, like preprandial hyperglycemia, contributes to elevated A1C levels, with its relative contribution being greater at A1C levels that are closer to 7% (53 mmol/mol). However, outcome studies have clearly shown A1C to be the primary predictor of complications, and landmark trials of glycemic control such as the DCCT and UKPDS relied overwhelmingly on preprandial SMBG. Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (42). Therefore, it is reasonable for postprandial testing to be recommended for individuals who have premeal glucose values within target but have A1C values above target. Measuring postprandial plasma glucose 1–2 h after the start of a meal and using treatments aimed at reducing postprandial plasma glucose values to <180 mg/dL (10.0 mmol/L) may help to lower A1C.

View this table:
Table 6.2

Summary of glycemic recommendations for many nonpregnant adults with diabetes

An analysis of data from 470 participants in the ADAG study (237 with type 1 diabetes and 147 with type 2 diabetes) found that actual average glucose levels associated with conventional A1C targets were higher than older DCCT and ADA targets (Table 6.1) (7,43). These findings support that premeal glucose targets may be relaxed without undermining overall glycemic control as measured by A1C. These data prompted the revision in the ADA-recommended premeal glucose target to 80–130 mg/dL (4.4–7.2 mmol/L) but did not affect the definition of hypoglycemia.

HYPOGLYCEMIA

Recommendations

  • 6.8 Individuals at risk for hypoglycemia should be asked about symptomatic and asymptomatic hypoglycemia at each encounter. C

  • 6.9 Glucose (15–20 g) is the preferred treatment for the conscious individual with blood glucose <70 mg/dL [3.9 mmol/L]), although any form of carbohydrate that contains glucose may be used. Fifteen minutes after treatment, if SMBG shows continued hypoglycemia, the treatment should be repeated. Once SMBG returns to normal, the individual should consume a meal or snack to prevent recurrence of hypoglycemia. E

  • 6.10 Glucagon should be prescribed for all individuals at increased risk of level 2 hypoglycemia, defined as blood glucose <54 mg/dL (3.0 mmol/L), so it is available should it be needed. Caregivers, school personnel, or family members of these individuals should know where it is and when and how to administer it. Glucagon administration is not limited to health care professionals. E

  • reverses diabetes type 2 charts (☑ statistics) | reverses diabetes type 2 januviahow to reverses diabetes type 2 for 6.11 Hypoglycemia unawareness or one or more episodes of level 3 hypoglycemia should trigger reevaluation of the treatment regimen. E

  • reverses diabetes type 2 questionnaire tool (👍 natural cures treatments) | reverses diabetes type 2 headachehow to reverses diabetes type 2 for 6.12 Insulin-treated patients with hypoglycemia unawareness or an episode the 1 last update 25 May 2020 of level 2 hypoglycemia should be advised to raise their glycemic targets to strictly avoid hypoglycemia for at least several weeks in order to partially reverse hypoglycemia unawareness and reduce risk of future episodes. A6.12 Insulin-treated patients with hypoglycemia unawareness or an episode of level 2 hypoglycemia should be advised to raise their glycemic targets to strictly avoid hypoglycemia for at least several weeks in order to partially reverse hypoglycemia unawareness and reduce risk of future episodes. A

  • 6.13 Ongoing assessment of cognitive function is suggested with increased vigilance for hypoglycemia by the clinician, patient, and caregivers if low cognition or declining cognition is found. B

Hypoglycemia is the major limiting factor in the glycemic management of type 1 and type 2 diabetes. Recommendations regarding the classification of hypoglycemia are outlined in Table 6.3 (44). Level 1 hypoglycemia is defined as a measurable glucose concentration <70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L). A blood glucose concentration of 70 mg/dL (3.9 mmol/L) has been recognized as a threshold for neuroendocrine responses to falling glucose in people without diabetes. Because many people with diabetes demonstrate impaired counterregulatory responses to hypoglycemia and/or experience hypoglycemia unawareness, a measured glucose level <70 mg/dL (3.9 mmol/L) is considered clinically important, independent of the severity of acute hypoglycemic symptoms. Level 2 hypoglycemia (defined as a blood glucose concentration <54 mg/dL [3.0 mmol/L]) is the threshold at which neuroglycopenic symptoms begin to occur and requires immediate action to resolve the hypoglycemic event. Lastly, level 3 hypoglycemia is defined as a severe event characterized by altered mental and/or physical functioning that requires assistance from another person for recovery.

reverses diabetes type 2 vaccine (☑ and alcohol) | reverses diabetes type 2 juvenilehow to reverses diabetes type 2 for View this table:
Table 6.3

Classification of hypoglycemia (44)

reverses diabetes type 2 treatment guidelines (🔥 autoimmune) | reverses diabetes type 2 guidelines 2020how to reverses diabetes type 2 for Studies of rates of level 3 hypoglycemia that rely on claims data for hospitalization, emergency department visits, and ambulance use substantially underestimate rates of level 3 hypoglycemia (45), yet find high burden of hypoglycemia in adults over 60 years of age in the community (46). African Americans are at substantially increased risk of level 3 hypoglycemia (46,47). In addition to age and race, other important risk factors found in a community-based epidemiologic cohort of older black and white adults with type 2 diabetes include insulin use, poor or moderate versus good glycemic control, albuminuria, and poor cognitive function (46).

Symptoms of hypoglycemia include, but are not limited to, shakiness, irritability, confusion, tachycardia, and hunger. Hypoglycemia may be inconvenient or frightening to patients with diabetes. Level 3 hypoglycemia may be recognized or unrecognized and can progress to loss of consciousness, seizure, coma, or death. It is reversed by administration of rapid-acting glucose or glucagon. Hypoglycemia can cause acute harm to the person with diabetes or others, especially if it causes falls, motor vehicle accidents, or other injury. A large cohort study suggested that among older adults with type 2 diabetes, a history of level 3 hypoglycemia was associated with greater risk of dementia (48). Conversely, in a substudy of the ACCORD trial, cognitive impairment at baseline or decline in cognitive function during the trial was significantly associated with subsequent episodes of level 3 hypoglycemia (49). Evidence from DCCT/EDIC, which involved adolescents and younger adults with type 1 diabetes, found no association between frequency of level 3 hypoglycemia and cognitive decline (50), as discussed in Section 13 “Children and Adolescents.”

Level 3 hypoglycemia was associated with mortality in participants in both the standard and the intensive glycemia arms of the ACCORD trial, but the relationships between hypoglycemia, achieved A1C, and treatment intensity were not straightforward. An association of level 3 hypoglycemia with mortality was also found in the ADVANCE trial (51). An association between self-reported level 3 hypoglycemia and 5-year mortality has also been reported in clinical practice (52)

Young children with type 1 diabetes and the elderly, including those with type 1 and type 2 diabetes (48,53), are noted as particularly vulnerable to hypoglycemia because of their reduced ability to recognize hypoglycemic symptoms and effectively communicate their needs. Individualized glucose targets, patient education, dietary intervention (e.g., bedtime snack to prevent overnight hypoglycemia when specifically needed to treat low blood glucose), exercise management, medication adjustment, glucose monitoring, and routine clinical surveillance may improve patient outcomes (54). CGM with automated low glucose suspend has been shown to be effective in reducing hypoglycemia in type 1 diabetes (55). For patients with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, human islet transplantation may be an option, but the approach remains experimental (56,57).

In 2015, the ADA changed its preprandial glycemic target from 70–130 mg/dL (3.9–7.2 mmol/L) to 80–130 mg/dL (4.4–7.2 mmol/L). This change reflects the results of the ADAG study, which demonstrated that higher glycemic targets corresponded to A1C goals (7). An additional goal of raising the lower range of the glycemic target was to limit overtreatment and provide a safety margin in patients titrating glucose-lowering drugs such as insulin to glycemic targets.

Hypoglycemia Treatment

Providers should continue to counsel patients to treat hypoglycemia with fast-acting carbohydrates at the hypoglycemia alert value of 70 mg/dL (3.9 mmol/L) or less. Hypoglycemia treatment requires ingestion of glucose- or carbohydrate-containing foods. The acute glycemic response correlates better with the glucose content of food than with the carbohydrate content of food. Pure glucose is the preferred treatment, but any form of carbohydrate that contains glucose will raise blood glucose. Added fat may retard and then prolong the acute glycemic response. In type 2 diabetes, ingested protein may increase insulin response without increasing plasma glucose concentrations (58). Therefore, carbohydrate sources high in protein should not be used to treat or prevent hypoglycemia. Ongoing insulin activity or insulin secretagogues may lead to recurrent hypoglycemia unless more food is ingested after recovery. Once the glucose returns to normal, the individual should be counseled to eat a meal or snack to prevent recurrent hypoglycemia.

reverses diabetes type 2 korean (👍 home remedies) | reverses diabetes type 2 questionnairehow to reverses diabetes type 2 for Glucagon

The use of glucagon is indicated for the treatment of hypoglycemia in people unable or unwilling to consume carbohydrates by mouth. Those in close contact with, or having custodial care of, people with hypoglycemia-prone diabetes (family members, roommates, school personnel, child care providers, correctional institution staff, or coworkers) should be instructed on the use of glucagon kits, including where the kit is and when and how to administer glucagon. An individual does not need to be a health care professional to safely administer glucagon. Care should be taken to ensure that glucagon kits are not expired.

Hypoglycemia Prevention

Hypoglycemia prevention is a critical component of diabetes management. SMBG and, for some patients, CGM are essential tools to assess therapy and detect incipient hypoglycemia. Patients should understand situations that increase their risk of hypoglycemia, such as when fasting for tests or procedures, when meals are delayed, during and after the consumption of alcohol, during and after intense exercise, and during sleep. Hypoglycemia may increase the risk of harm to self or others, such as with driving. Teaching people with diabetes to balance insulin use and carbohydrate intake and exercise are necessary, but these strategies are not always sufficient for prevention.

In type 1 diabetes and severely insulin-deficient type 2 diabetes, hypoglycemia unawareness (or hypoglycemia-associated autonomic failure) can severely compromise stringent diabetes control and quality of life. This syndrome is characterized by deficient counterregulatory hormone release, especially in older adults, and a diminished autonomic response, which both are risk factors for, and caused by, hypoglycemia. A corollary to this “vicious cycle” is that several weeks of avoidance of hypoglycemia has been demonstrated to improve counterregulation and hypoglycemia awareness in many patients (59). Hence, patients with one or more episodes of clinically significant hypoglycemia may benefit from at least short-term relaxation of glycemic targets.

INTERCURRENT ILLNESS

For further information on management of patients with hyperglycemia in the hospital, please refer to Section 15 “Diabetes Care in the Hospital.”

Stressful events (e.g., illness, trauma, surgery, etc.) may worsen glycemic control and precipitate diabetic ketoacidosis or nonketotic hyperglycemic hyperosmolar state, life-threatening conditions that require immediate medical care to prevent complications and death. Any condition leading to deterioration in glycemic control necessitates more frequent monitoring of blood glucose; ketosis-prone patients also require urine or blood ketone monitoring. If accompanied by ketosis, vomiting, or alteration in the level of consciousness, marked hyperglycemia requires temporary adjustment of the treatment regimen and immediate interaction with the diabetes care team. The patient treated with noninsulin therapies or medical nutrition therapy alone may require insulin. Adequate fluid and caloric intake must be ensured. Infection or dehydration is more likely to necessitate hospitalization of the person with diabetes than the person without diabetes.

A physician with expertise in diabetes management should treat the hospitalized patient. For further information on the management of diabetic ketoacidosis and the nonketotic hyperglycemic hyperosmolar state, please refer to the ADA consensus report “Hyperglycemic Crises in Adult Patients With Diabetes” (60).

Footnotes

  • Suggested citation: American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes—2019. Diabetes Care 2019;42(Suppl. 1):S61–S70

  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

reverses diabetes type 2 mellitus definition (⭐️ eating plan) | reverses diabetes type 2 foot painhow to reverses diabetes type 2 for Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

    1. Laiteerapong N,
    2. Ham SAHam SA,
    3. Gao YGao Y, et al
    . The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study). Diabetes Care. In press
    1. Stratton IM,
    2. reverses diabetes type 2 characteristics (☑ guidelines) | reverses diabetes type 2 symptoms nhshow to reverses diabetes type 2 for for 1 last update 25 May 2020 AdlerAdler the 1 last update 25 May 2020 AIAI,
    3. reverses diabetes type 2 variation (⭐️ blood test) | reverses diabetes type 2 and alcoholhow to reverses diabetes type 2 for Neil HAW, et al
    . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ reverses diabetes type 2 natural remedy (⭐️ zero carb) | reverses diabetes type 2 normalhow to reverses diabetes type 2 for 2000;321:405412
    1. Little RR,
    2. Rohlfing the 1 last update 25 May 2020 CLCL,
    3. reverses diabetes type 2 natural cure (☑ mellitus is primarily a problem with) | reverses diabetes type 2 medicationshow to reverses diabetes type 2 for for 1 last update 25 May 2020 SacksSacks DB; National Glycohemoglobin Standardization Program (NGSP) Steering Committee
    . Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011;57: for 1 last update 25 May 2020 205205214
    1. Jovanovič L,
    2. Savas H,
    3. Mehta MMehta M,
    4. Trujillo A,
    5. reverses diabetes type 2 lipid (🔴 therapeutic) | reverses diabetes type 2 edemahow to reverses diabetes type 2 for Pettitt reverses diabetes type 2 naturally (⭐️ symptoms) | reverses diabetes type 2 yogurthow to reverses diabetes type 2 for DJ
    . Frequent monitoring of A1C during pregnancy as a treatment tool to guide therapy. Diabetes Care 2011;34:5354
    1. Beck RW,
    2. Connor reverses diabetes type 2 range chart (⭐️ and hypothyroidism) | reverses diabetes type 2 vs 1how to reverses diabetes type 2 for CG,
    3. Mullen DM,
    4. Wesley DM,
    5. reverses diabetes type 2 ketone (🔥 veteran) | reverses diabetes type 2 treatment insulinhow to reverses diabetes type 2 for Bergenstal RM
    . The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 2017;40:994999
    1. Nathan for 1 last update 25 May 2020 DMDM,
    2. reverses diabetes type 2 overview (👍 dinner menu) | reverses diabetes type 2 with weight losshow to reverses diabetes type 2 for reverses diabetes type 2 song (⭐️ jokes) | reverses diabetes type 2 treathow to reverses diabetes type 2 for Kuenen J,
    3. Borg RBorg R,
    4. Zheng H,
    5. Schoenfeld D,
    6. Heine RJ; A1c-Derived Average Glucose Study Group
    . Translating the A1C assay into estimated average glucose values. Diabetes Care the 1 last update 25 May 2020 20082008;31:14731478
    1. Wei reverses diabetes type 2 glucose levels chart (☑ onset age) | reverses diabetes type 2 Treatmentshow to reverses diabetes type 2 for N,
    2. Zheng H,
    3. Nathan DM
    . Empirically establishing blood glucose targets to achieve HbA1c goals. Diabetes Care 2014;37:10481051
    1. Selvin E
    . Are there clinical implications of racial differences in HbA1c? A difference, to be a difference, must make a difference. Diabetes Care 2016;39:14621467
    1. Bergenstal RM,
    2. Gal RL,
    3. Connor CG, et al.; T1D Exchange Racial Differences Study Group
    . Racial differences in the relationship of glucose for 1 last update 25 May 2020 concentrations and hemoglobin A1c levelsRacial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med 2017;167:95102
    1. Lacy for 1 last update 25 May 2020 MEME,
    2. Wellenius reverses diabetes type 2 options (🔴 breakfast menu) | reverses diabetes type 2 oliveshow to reverses diabetes type 2 for GA,
    3. Sumner AE, et al
    . Association of sickle cell trait with hemoglobin A1c in African Americans. JAMA for 1 last update 25 May 2020 20172017;317:507515
    1. Rohlfing C,
    2. Hanson the 1 last update 25 May 2020 SS,
    3. Little RR
    . reverses diabetes type 2 genetic link (☑ exercise plan) | reverses diabetes type 2 brochurehow to reverses diabetes type 2 for Measurement of hemoglobin A1c in patients with sickle cell trait. JAMA 2017;317:2237
    1. Wheeler reverses diabetes type 2 level (🔥 pregnancy) | reverses diabetes type 2 straight talkhow to reverses diabetes type 2 for E,
    2. Leong A,
    3. reverses diabetes type 2 treatment studies (🔥 numbers) | reverses diabetes type 2 quick fixhow to reverses diabetes type 2 for Liu C-T, et al.; EPIC-CVD Consortium; EPIC-InterAct the 1 last update 25 May 2020 ConsortiumEPIC-InterAct Consortium; Lifelines Cohort Study
    . Impact of common genetic determinants of hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: a transethnic genome-wide meta-analysis. PLoS Med 2017;14:reverses diabetes type 2 exercise (🔥 lab values) | reverses diabetes type 2 treatment nhshow to reverses diabetes type 2 for e1002383
    1. Wilson DM,
    2. Kollman; Diabetes Research in Children Network (DirecNet) Study Group
    . Relationship of A1C to glucose concentrations in children with type 1 diabetes: assessments by high-frequency glucose determinations by sensors. Diabetes Care 2008;31:381385
    1. for 1 last update 25 May 2020 BuseBuse JB,
    2. for 1 last update 25 May 2020 KaufmanKaufman FR,
    3. reverses diabetes type 2 herbs (🔴 and obesity) | reverses diabetes type 2 remissionhow to reverses diabetes type 2 for Linder B,
    4. Hirst K,
    5. El for 1 last update 25 May 2020 GhormliEl Ghormli L,
    6. Willi SWilli S; HEALTHY Study Group
    . Diabetes screening with hemoglobin A1c versus fasting plasma the 1 last update 25 May 2020 glucose in a multiethnic middle-school cohortDiabetes screening with hemoglobin A1c versus fasting plasma glucose in a multiethnic middle-school cohort. Diabetes Care reverses diabetes type 2 high blood sugar symptoms (☑ breakfast) | reverses diabetes type 2 type 1how to reverses diabetes type 2 for 2013;36:429435
    1. Kamps the 1 last update 25 May 2020 JLJL,
    2. Hempe the 1 last update 25 May 2020 JMJM,
    3. Chalew SA
    . Racial disparity in A1C independent of mean blood glucose in children with type 1 diabetes. Diabetes Care 2010;33:1025 the 1 last update 25 May 2020 10271027
    1. Diabetes Control and Complications Trial Research Group
    . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:reverses diabetes type 2 high blood sugar symptoms (👍 insulin pump) | reverses diabetes type 2 breadhow to reverses diabetes type 2 for 977reverses diabetes type 2 pathophys (🔥 natural dressings) | reverses diabetes type 2 diagnostichow to reverses diabetes type 2 for 986
    1. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
    . Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of the 1 last update 25 May 2020 follow-up in the DCCT/EDICEffect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes 2015;64:631642
    1. reverses diabetes type 2 blood test (🔥 doctor near me) | reverses diabetes type 2 chartshow to reverses diabetes type 2 for Lachin JM,
    2. Genuth reverses diabetes type 2 danger zone (⭐️ sugar level) | reverses diabetes type 2 epidemiologyhow to reverses diabetes type 2 for S,
    3. Cleary P,
    4. Davis MD,
    5. the 1 last update 25 May 2020 NathanNathan DM; reverses diabetes type 2 diagnostic procedures (⭐️ cause high blood pressure) | reverses diabetes type 2 in ushow to reverses diabetes type 2 for Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
    . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy [published correction appears in N Engl J Med 2000;342:1376]. N Engl J Med 2000;342:381389
    1. Ohkubo Y,
    2. Kishikawa the 1 last update 25 May 2020 HH,
    3. Araki E, et al
    . Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28: the 1 last update 25 May 2020 103103reverses diabetes type 2 treatments google search (👍 graph) | reverses diabetes type 2 quorahow to reverses diabetes type 2 for 117
    1. UK Prospective Diabetes Study (UKPDS) Group
    . reverses diabetes type 2 snacks (🔥 treatment home remedies) | reverses diabetes type 2 in hindihow to reverses diabetes type 2 for Effect of intensive blood-glucose control with metformin on complications in overweight patients for 1 last update 25 May 2020 with type 2 diabetes (UKPDS 34)Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854865
    1. UK the 1 last update 25 May 2020 Prospective Diabetes Study (UKPDS) GroupUK Prospective Diabetes Study (UKPDS) Group
    . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet for 1 last update 25 May 2020 19981998;352:837reverses diabetes type 2 occur (☑ quora) | reverses diabetes type 2 test kithow to reverses diabetes type 2 for 853
    1. Holman RR,
    2. the 1 last update 25 May 2020 PaulPaul SK,
    3. Bethel reverses diabetes type 2 fruits (🔴 options) | reverses diabetes type 2 lipidhow to reverses diabetes type 2 for MA,
    4. Matthews DR,
    5. Neil the 1 last update 25 May 2020 HAWHAW
    . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:15771589
    1. Adler AI,
    2. Stratton reverses diabetes type 2 e119 (👍 occur) | reverses diabetes type 2 home remedies forhow to reverses diabetes type 2 for IM,
    3. reverses diabetes type 2 glucose levels chart (🔴 natural remedy) | reverses diabetes type 2 ankle swellinghow to reverses diabetes type 2 for Neil HAW, et al
    . Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:reverses diabetes type 2 glucose levels chart (⭐️ food plan) | reverses diabetes type 2 metforminhow to reverses diabetes type 2 for 412 for 1 last update 25 May 2020 419419
    1. Duckworth W,
    2. Abraira C,
    3. Moritz T, et al.; VADT Investigators
    . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360: for 1 last update 25 May 2020 129129139
    1. Patel A,
    2. MacMahon S,
    3. Chalmers J, reverses diabetes type 2 high blood sugar (☑ odor) | reverses diabetes type 2 by racehow to reverses diabetes type 2 for et for 1 last update 25 May 2020 alet al.; ADVANCE Collaborative Group
    . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; the 1 last update 25 May 2020 358358:25602572
    1. Ismail-Beigi FIsmail-Beigi F,
    2. Craven T,
    3. Banerji MA, et al.; ACCORD trial group
    . Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419430
    1. Gerstein HC,
    2. Miller ME,
    3. Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group
    . reverses diabetes type 2 vbid (🔥 go away) | reverses diabetes type 2 yogahow to reverses diabetes type 2 for Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:25452559
    1. Nathan reverses diabetes type 2 breakfast menu (☑ quotes) | reverses diabetes type 2 sodahow to reverses diabetes type 2 for DM,
    2. Cleary PA,
    3. Backlund J-YC, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group
    . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med reverses diabetes type 2 would be considered (☑ insulin resistance) | reverses diabetes type 2 valueshow to reverses diabetes type 2 for 2005;353:reverses diabetes type 2 vision (🔥 statistics) | reverses diabetes type 2 vitamind3how to reverses diabetes type 2 for 2643reverses diabetes type 2 treatment home remedies (👍 carbohydrate) | reverses diabetes type 2 explainedhow to reverses diabetes type 2 for 2653
    1. Nathan DM,
    2. Zinman B,
    3. reverses diabetes type 2 lunch (🔴 nursing) | reverses diabetes type 2 occurs whenhow to reverses diabetes type 2 for Cleary PA, et for 1 last update 25 May 2020 alet al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group
    . Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh for 1 last update 25 May 2020 Epidemiology of Diabetes Complications experience (1983–2005)Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005). Arch Intern Med 2009;169:13071316
    1. Orchard reverses diabetes type 2 how do you get it (🔥 mellitus nature reviews disease primers) | reverses diabetes type 2 ncbihow to reverses diabetes type 2 for the 1 last update 25 May 2020 TJTJ,
    2. reverses diabetes type 2 onset (🔥 quizlet) | reverses diabetes type 2 chartshow to reverses diabetes type 2 for Nathan DM,
    3. reverses diabetes type 2 compared to type 1 (🔥 natural remedies) | reverses diabetes type 2 is characterized byhow to reverses diabetes type 2 for Zinman B, reverses diabetes type 2 questions for dr (🔥 symptoms in children) | reverses diabetes type 2 junk foodhow to reverses diabetes type 2 for et al.; Writing Group for the DCCT/EDIC Research Group
    . Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45 for 1 last update 25 May 2020 5353
    1. reverses diabetes type 2 teenager (⭐️ teens) | reverses diabetes type 2 with chronic kidney diseasehow to reverses diabetes type 2 for Skyler JS,
    2. Bergenstal reverses diabetes type 2 blood test (👍 reversal) | reverses diabetes type 2 blood sugar levelshow to reverses diabetes type 2 for R,
    3. Bonow the for 1 last update 25 May 2020 1 last update 25 May 2020 ROROBonow the 1 last update 25 May 2020 RORO, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association
    . Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:reverses diabetes type 2 immune system (⭐️ journal articles) | reverses diabetes type 2 would be consideredhow to reverses diabetes type 2 for 187192
    1. Zoungas S,
    2. reverses diabetes type 2 health promotion (🔥 food list) | reverses diabetes type 2 glucosehow to reverses diabetes type 2 for Chalmers J,
    3. Neal for 1 last update 25 May 2020 BB, et al.; ADVANCE-ON Collaborative Group
    . reverses diabetes type 2 kidshealth (🔴 pills) | reverses diabetes type 2 statistics ukhow to reverses diabetes type 2 for Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371: for 1 last update 25 May 2020 139213921406
    1. Hayward RA,
    2. reverses diabetes type 2 treatment and prevention (⭐️ vision) | reverses diabetes type 2 ketonehow to reverses diabetes type 2 for Reaven PD,
    3. for 1 last update 25 May 2020 WiitalaWiitala WL, et al.; VADT Investigators
    . Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; for 1 last update 25 May 2020 372372: for 1 last update 25 May 2020 219721972206
    1. Turnbull FM,
    2. reverses diabetes type 2 normal range chart (⭐️ pumps system) | reverses diabetes type 2 veganhow to reverses diabetes type 2 for Abraira C,
    3. Anderson RJ, et al.; Control Group
    . Intensive glucose control and macrovascular outcomes in type 2 the 1 last update 25 May 2020 diabetesIntensive glucose control and macrovascular outcomes in type 2 diabetes [published correction appears in Diabetologia 2009;52:2470]. Diabetologia for 1 last update 25 May 2020 20092009;52:22882298
    1. Duckworth the 1 last update 25 May 2020 WCWC,
    2. Abraira C,
    3. Moritz TE, et al.; Investigators of the VADT
    . The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications reverses diabetes type 2 straight talk (🔥 jokes) | reverses diabetes type 2 ketones in urinehow to reverses diabetes type 2 for 2011;25: the 1 last update 25 May 2020 355355361
    1. Lipska KJ,
    2. reverses diabetes type 2 blood sugar chart (👍 means) | reverses diabetes type 2 natural cures treatmentshow to reverses diabetes type 2 for Ross for 1 last update 25 May 2020 JSJS,
    3. Miao Y,
    4. Shah reverses diabetes type 2 medicine which aetna pays for (👍 wild rice) | reverses diabetes type 2 glucose rangehow to reverses diabetes type 2 for ND,
    5. Lee SJ,
    6. Steinman reverses diabetes type 2 youth statistics in usa (☑ physiology) | reverses diabetes type 2 carbs allowed per dayhow to reverses diabetes type 2 for MA
    . Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 2015;175:356362
    1. reverses diabetes type 2 japan (👍 e119) | reverses diabetes type 2 in youthhow to reverses diabetes type 2 for Vijan S,
    2. Sussman JB,
    3. Yudkin JS,
    4. for 1 last update 25 May 2020 HaywardHayward RA
    . Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med reverses diabetes type 2 herpes (☑ urination) | reverses diabetes type 2 natural curehow to reverses diabetes type 2 for the 1 last update 25 May 2020 20142014;174:12271234
    1. Lee AK,
    2. Warren reverses diabetes type 2 joint pain (☑ youth statistics in usa) | reverses diabetes type 2 treatments lexingtonhow to reverses diabetes type 2 for B,
    3. Lee CJ, et al
    . The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care 2018;41:104111
    1. Davies for 1 last update 25 May 2020 MJMJ,
    2. D’Alessio DA,
    3. for 1 last update 25 May 2020 FradkinFradkin J, et al
    . Management of hyperglycemia for 1 last update 25 May 2020 in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; for 1 last update 25 May 2020 4141:2669reverses diabetes type 2 life expectancy (☑ and covid-19) | reverses diabetes type 2 genehow to reverses diabetes type 2 for 2701
    1. Inzucchi SE,
    2. Bergenstal RMBergenstal RM,
    3. Buse the 1 last update 25 May 2020 JBJB, et al
    . reverses diabetes type 2 natural dressings (🔥 food list) | reverses diabetes type 2 with hyperglycemiahow to reverses diabetes type 2 for Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140149
    1. American Diabetes Association
    . reverses diabetes type 2 treatment nih (⭐️ overview) | reverses diabetes type 2 case studyhow to reverses diabetes type 2 for Postprandial blood glucose. Diabetes Care 2001;reverses diabetes type 2 breakfast (🔥 treatment guidelines) | reverses diabetes type 2 rangehow to reverses diabetes type 2 for 24:775778
    1. Raz I,
    2. Wilson reverses diabetes type 2 underweight (☑ video) | reverses diabetes type 2 medicine which aetna pays forhow to reverses diabetes type 2 for PWF,
    3. Strojek KStrojek K, et al
    . Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381386
    1. Albers JW,
    2. Herman WH,
    3. Pop-Busui R, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
    . Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Diabetes Care 2010;33:10901096
    1. Agiostratidou G,
    2. reverses diabetes type 2 limits (☑ brochure) | reverses diabetes type 2 insulin resistancehow to reverses diabetes type 2 for Anhalt HAnhalt H,
    3. Ball D, et al
    . Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care reverses diabetes type 2 diagnostic procedures (👍 medications) | reverses diabetes type 2 zipper pullshow to reverses diabetes type 2 for 2017;40: for 1 last update 25 May 2020 162216221630
    1. reverses diabetes type 2 high blood sugar symptoms (🔥 youngest age in pediatrics) | reverses diabetes type 2 treatments vinegarhow to reverses diabetes type 2 for Karter AJ,
    2. reverses diabetes type 2 explained (👍 foot pain) | reverses diabetes type 2 herpeshow to reverses diabetes type 2 for Moffet HH,
    3. Liu JY,
    4. Lipska KJLipska KJ
    . Surveillance of hypoglycemia—limitations of emergency department and hospital utilization data. JAMA Intern Med 2018;178:987988
    1. Lee AK,
    2. Lee CJLee CJ,
    3. reverses diabetes type 2 definition (🔴 list) | reverses diabetes type 2 pregnancyhow to reverses diabetes type 2 for the 1 last update 25 May 2020 HuangHuang ES,
    4. Sharrett AR,
    5. Coresh J,
    6. Selvin the 1 last update 25 May 2020 EE
    . Risk factors for severe hypoglycemia in black and white adults with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2017;40:16611667
    1. Karter AJ,
    2. Lipska reverses diabetes type 2 jardiance (👍 treatment diet) | reverses diabetes type 2 biologyhow to reverses diabetes type 2 for KJ,
    3. reverses diabetes type 2 mellitus with hyperglycemia (☑ dinner recipes) | reverses diabetes type 2 logbookhow to reverses diabetes type 2 for O’Connor PJ, et al.; reverses diabetes type 2 journal articles (🔥 glut4) | reverses diabetes type 2 riskhow to reverses diabetes type 2 for SUPREME-DM Study Group
    . reverses diabetes type 2 and exercise (👍 pathophys) | reverses diabetes type 2 questionnairehow to reverses diabetes type 2 for High rates of severe hypoglycemia among African American patients with diabetes: the SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) network. J Diabetes Complications 2017;31:869873
    1. Whitmer RA,
    2. reverses diabetes type 2 usually appears after age 40 (🔴 mellitus nature reviews disease primers) | reverses diabetes type 2 with diethow to reverses diabetes type 2 for Karter reverses diabetes type 2 pathogenesis (👍 metformin) | reverses diabetes type 2 herbshow to reverses diabetes type 2 for AJ,
    3. Yaffe K,
    4. Quesenberry reverses diabetes type 2 ribbon (🔴 mellitus nature reviews disease primers) | reverses diabetes type 2 what to eathow to reverses diabetes type 2 for CP Jr,
    5. reverses diabetes type 2 soda (☑ explanation) | reverses diabetes type 2 symptomshow to reverses diabetes type 2 for Selby JV
    . Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:15651572
    1. Punthakee Z,
    2. Miller reverses diabetes type 2 mayo clinic (⭐️ options) | reverses diabetes type 2 naturalhow to reverses diabetes type 2 for ME,
    3. reverses diabetes type 2 compared to type 1 (☑ vitamin d) | reverses diabetes type 2 breakfasthow to reverses diabetes type 2 for Launer LJ, et al.; ACCORD Group of Investigators; ACCORD-MIND Investigators
    . Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care reverses diabetes type 2 natural (👍 menu diet) | reverses diabetes type 2 zero carbhow to reverses diabetes type 2 for 2012;35:787793
    1. Jacobson the 1 last update 25 May 2020 AMAM,
    2. reverses diabetes type 2 symptoms nhs (👍 with fasting) | reverses diabetes type 2 journal articleshow to reverses diabetes type 2 for Musen G,
    3. the 1 last update 25 May 2020 RyanRyan CM, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group
    . Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007;356:reverses diabetes type 2 teenager (👍 insulin pump) | reverses diabetes type 2 physiologyhow to reverses diabetes type 2 for 18421852
    1. reverses diabetes type 2 quick fix (👍 patho) | reverses diabetes type 2 linkhow to reverses diabetes type 2 for Zoungas S,
    2. Patel A,
    3. Chalmers J, et al.; ADVANCE Collaborative Group
    . Severe hypoglycemia and risks of vascular events and death. N Engl J Med reverses diabetes type 2 intervention (👍 urination) | reverses diabetes type 2 edemahow to reverses diabetes type 2 for 2010;363:14101418
    1. McCoy RG,
    2. Van Houten HK,
    3. Ziegenfuss reverses diabetes type 2 keto diet (🔴 lab tests) | reverses diabetes type 2 lunchhow to reverses diabetes type 2 for JY,
    4. Shah ND,
    5. reverses diabetes type 2 with keto (☑ jewelry) | reverses diabetes type 2 mellitus without complicationhow to reverses diabetes type 2 for Wermers RAWermers RA,
    6. reverses diabetes type 2 young age (👍 treatment guidelines) | reverses diabetes type 2 physiologyhow to reverses diabetes type 2 for Smith for 1 last update 25 May 2020 SASA
    . Increased mortality the 1 last update 25 May 2020 of patients with diabetes reporting severe hypoglycemiaIncreased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012;35:18971901
    1. DuBose SN,
    2. Weinstock RS,
    3. Beck RW, et al
    . Hypoglycemia in older adults with type 1 diabetes. Diabetes Technol Ther 2016;18:765reverses diabetes type 2 with mellitus (☑ take insulin) | reverses diabetes type 2 Treatmentshow to reverses diabetes type 2 for 771
    1. Seaquist ER,
    2. Anderson J,
    3. reverses diabetes type 2 natural remedy (⭐️ undiagnosed) | reverses diabetes type 2 symptoms womenhow to reverses diabetes type 2 for Childs B, et al
    . Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:13841395
    1. Bergenstal the 1 last update 25 May 2020 RMRM,
    2. Klonoff DC,
    3. Garg SK, et al.; reverses diabetes type 2 diet plan (🔴 young) | reverses diabetes type 2 eventshow to reverses diabetes type 2 for ASPIRE In-Home Study Group
    . Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med for 1 last update 25 May 2020 20132013;369:224232
    1. Hering BJHering BJ,
    2. reverses diabetes type 2 on insulin (⭐️ lab values) | reverses diabetes type 2 essayhow to reverses diabetes type 2 for Clarke reverses diabetes type 2 food chart (☑ your guide to getting started) | reverses diabetes type 2 fruits to eathow to reverses diabetes type 2 for WR,
    3. for 1 last update 25 May 2020 BridgesBridges ND, et the 1 last update 25 May 2020 alet al.; Clinical Islet Transplantation Consortium
    . Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care 2016;39:12301240
    1. Harlan DM
    . Islet transplantation for hypoglycemia unawareness/severe hypoglycemia: caveat emptor. Diabetes Care for 1 last update 25 May 2020 20162016;39:10721074
    1. Layman the 1 last update 25 May 2020 DKDK,
    2. Clifton P,
    3. Gannon MC,
    4. Krauss RM,
    5. Nuttall FQ
    . Protein in optimal health: heart disease and type 2 diabetes. Am J Clin Nutr 2008;87:1571S the 1 last update 25 May 2020 1575S1575S
    1. Cryer PE
    . Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2004;350: for 1 last update 25 May 2020 227222722279
    1. Kitabchi AE,
    2. Umpierrez GE,
    3. reverses diabetes type 2 eating (🔥 quote) | reverses diabetes type 2 questionnairehow to reverses diabetes type 2 for Miles for 1 last update 25 May 2020 JMJM,
    4. Fisher JN
    . Hyperglycemic crises for 1 last update 25 May 2020 in adult patients with diabetesHyperglycemic crises in adult patients with diabetes. Diabetes Care the 1 last update 25 May 2020 20092009;32:1335reverses diabetes type 2 too much insulin (🔴 pathophysiology) | reverses diabetes type 2 meal planhow to reverses diabetes type 2 for 1343
View Abstract

In this Issue

January for 1 last update 25 May 2020 2019, 42(Supplement 1)January 2019, 42(Supplement 1)
reverses diabetes type 2 cause hypertension (👍 bread) | reverses diabetes type 2 nursing diagnosishow to reverses diabetes type 2 for Sign up to receive current issue alerts
Sign In to Email Alerts with your Email Address

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association
Diabetes Care Jan the 1 last update 25 May 2020 2019, Jan 2019, 42 (Supplement 1) S61-S70; DOI: 10.2337/dc19-S006

6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association
reverses diabetes type 2 mellitus without complication (👍 ketones) | reverses diabetes type 2 mellitus definitionhow to reverses diabetes type 2 for Diabetes Care Jan 2019, 42 (Supplement 1) S61-S70; DOI: 10.2337/dc19-S006
reverses diabetes type 2 children (☑ urination) | reverses diabetes type 2 questionnaire toolhow to reverses diabetes type 2 for

Related Articles

Cited By...

reverses diabetes type 2 menu diet (🔴 numbers) | reverses diabetes type 2 woundshow to reverses diabetes type 2 for More in this TOC Section

Similar Articles